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Association between endothelin type A receptor haplotypes and mortality in coronary heart disease Coronary heart disease (CHD) encompasses a range of conditions including unstable angina, acute myocardial infarction (MI) and sudden ischemic death, characterized by the common pathophysiologic process of atherosclerotic plaque rupture and thrombosis [1, 2] . CHD patients with a high risk of poor clinical outcome are identified with the use of biochemical and clinical measurements, including circulating cardiac markers and echo cardiographic indices. Prognosis of patients varies widely and genetic factors are likely to play an important role in the pathogenesis and progression of disease. The identification of genes that influence progression of disease may inform future patient management and care.
The endothelins are a family of potent vasoconstrictors, identified in 1988 by Yanagisawa et al. in cultured porcine aortic endothelial cells [3] . Since this original discovery, three different isoforms of endothelin (ET-1, ET-2 and ET-3) have been identified, encoded by separate genes on chromosomes 6, 1 and 20, respectively [4, 5] . ET-1 is the best understood peptide, and is recognized as playing an important role in regulating vascular tone, cardiac contractility, salt/water homeostasis and the production of renin and aldosterone [6] . ET-1 is the most abundant of the endothelins, and although found in a variety of different tissues is produced predominantly in the vascular endothelium.
The important biological effects of endothelin are mediated by the G protein-coupled receptors, ETA and ETB, which are encoded by the EDNRA and EDNRB genes. ETA preferentially binds ET-1 and mediates its effects to promote vasoconstriction, cell growth, adhesion, fibrosis and thrombosis. Unlike ETA, the binding of endothelin to ETB promotes vasodilation. However in some tissues, such as the coronary arteries, vasoconstrictor effects have been observed [7] .
The EDNRA gene, located on chromosome 4 at position q31.22 spans over 63.97 kb, contains eight exons and more than 300 SNPs. Several of these gene variants have been associated with essential hypertension [8] , night systolic and diastolic blood pressure [9] , baroflex sensitivity [10] , pulse pressure in MI patients [11] , idiopathic dilated cardiomyopathy [12] and migraine [13] . However, like many genetic association studies, the findings to date are heterogeneous and the role that genetic variation in the EDNRA gene plays in the development and progression of CHD remains unclear. These studies have tended to focus on the effects of individual SNPs, with only one exploring the combined effects of several variants [9] .
The specific combination of alleles that occur on a single chromosome is referred to as a haplofuture science group and are often inherited in combination. The strong association between variants is referred to as linkage disequilibrium, and means that in many chromosome regions the common variation is accounted for by only a few haplotypes [14] . Determining the patterns of linkage disequilibrium within the genome is of huge practical value for genetic studies, and means that with careful selection a few SNPs will provide enough information to predict the genotype of other polymorphisms within that region. As a result, the common haplotypes within a region can be defined by genotyping only a few 'tag' SNPs. Haplotypes are therefore an extremely powerful tool for studying of the role of an entire gene region in complex human diseases [15, 16] .
Although individual EDNRA SNPs have been associated with susceptibility to hypertension and other cardiovascular disorders, no previous study has investigated the association of EDNRA gene variation with progression and outcome in established CHD. We have used a haplotyping approach to investigate whether a combination of polymorphisms within the EDNRA gene provides prognostic information in patients with coronary artery disease (CAD), independent of established cardiac risk factors. We hypothesized that common genetic variants in the EDNRA gene may result in altered receptor activity compared with the wild type alleles, making the heart and vasculature more susceptible to adverse remodeling, contributing to a poor prognosis in heart patients.
Methods
n Coronary disease cohort study From July 2002, patients admitted into either Christchurch Hospital or Auckland City Hospital (New Zealand) were recruited into the study using the following inclusion criteria, ischemic discomfort plus one or more of: ECG changes (ST segment depression or elevation of at least 0.5 mm, T-wave inversion of at least 3 mm in at least three leads or left bundle branch block); elevated levels of cardiac markers (troponin T >0.1 µg/l, creatine kinase >175 IU/l males or >150 IU/l females); a history of coronary disease; or age of at least 65 years in patients with diabetes or vascular disease. Patients were excluded from the study if they had a severe comorbidity (e.g., terminal cancer, end-stage kidney disease or end-stage heart failure) that limited their life expectancy to less than 3 years. The study intentionally included a broad spectrum of age, both genders and significant subgroups of patients with the important antecedent risk factors and disease processes such as hyper tension and diabetes. At the time of study design, the inclusion criteria was selected to be identical to those used in the OPUS-TIMI 16 trial [17] and reiterated in the New England Journal of Medicine article by de Lemos et al. discussing the prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [18] . Although recruitment was ongoing, the cohort reported in this study consisted of 1007 patients, of which 723 were recruited upon admission to Christchurch Hospital and 284 to Auckland City Hospital. Anthropometric and clinical characteristics and clinical events were recorded at planned followup clinic visits, and from questionnaires, patient notes and national health information services, and hospital patient management system databases. Patients were followed for up to 5 years from the time they were admitted into the study (median: 3. n Neurohormone assays, analyte measurement & echocardiography At the time of baseline visit, which ranged from between 5 and 56 days from the date of index admission, blood was collected into chilled ethyl enediaminetetraacetic acid tubes and stored on ice. Plasma was separated within 20 min by centrifugation and stored at -80°C until analyzed. Plasma was assayed for brain natriuretic peptide (BNP; intra-assay coefficient of variation [CV] = 6.8-16.1%, inter-assay CV = 14.9-24.2%) [19] and N-terminal BNP (NT-pro BNP; intra-assay CV = 3.5-9.4%, inter-assay CV = 6.2-13.2%) [20] . Transthoracic echocardiography was performed using a GE Vivid 3 ultrasound system (GE Medical Systems, USA) at Christchurch Hospital and an ATL HDI 5000 (Philips Healthcare, USA) at Auckland City Hospital. The standardized imaging protocol included apical 4-and 2-chamber views according to the American Society of Echocardiography [21] . Parasternal, short-and long-axis views (averaged over four cycles) were obtained for M-mode measurements of left ventricular dimensions. Biplane diastolic and systolic volumes and ejection fraction were calculated by planimetry according to Simpson's method.
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EDNRA haplotypes & mortality in coronary disease ReseaRch aRticle www.futuremedicine.com 3 future science group n DNA extraction & EDNRA genotyping DNA was extracted from whole blood as previously described [22] . Haploview analysis [23] of HapMap data for samples of Northern and Western European ancestry identified five haplotype blocks over the eight exons of the EDNRA gene. One common tag SNP (minor allele frequency >20%) was selected from each of the four major haplotype blocks. The minor haplotype block, located within an intronic region between exons 2 and 3, contained one tag SNP that occurred at a frequency of 12% and was not included (Figure 1 ). The SNPs selected for analysis were rs6537484 and rs1568136 from intron 2, rs10003447 from intron 3 and rs5335 from the untranslated region of exon 8. Patients were additionally genotyped for the His323His (rs5333) polymorphism from exon 6 of the EDNRA gene as this gene variant has been previously associated with essential hyper tension [8] ( Figure 1 ). Genotyping was conducted using the Applied Biosystems SNPlex geno typing Platform (Applied Biosystems, USA) with 100 ng of fragmented genomic DNA and an ABI PRISM 3130xl genetic analyzer (Applied Biosystems) [24, 25] . GeneMapper Software v4.0 (Applied Biosystems) was used to analyze the data and to assign the genotypes [24, 25] . Quality control was performed on >20% of all samples. Of the samples re-assayed 98.4% were concordant with the original genotype calls. Nonconcordant samples were evenly distributed between genotype groups and were removed from further analysis.
n Inference of haplotype PHASE software version 2.1 was used for haplotype reconstruction and to estimate population haplotype frequencies [26, 27] . Patients with missing genotype data were removed from the analysis.
n Statistical analysis For all analyses patients were grouped according to their number of copies of haplotype 1 (the haplotype with the greatest allele frequency and defined by the major allele at each SNP locus). All analyses were performed using an additive genetic model. Associations between haplotype and demographics, neurohormones and echocardiographic measurements were assessed using c 2 and analysis of variance (ANOVA). Hormone data consistently exhibited skewed distributions and were log-transformed before analysis. The survival of each haplotype group (0, 1 and 2 copies of the major haplotype) was assessed using Kaplan-Meier survival analysis and the log-rank test statistic. Independent associations between haplotype group and survival was tested using Cox proportional hazards multivariate analysis including the established cardiovascular risk factors: age of coronary disease onset; gender; ethnicity; prior history of myocardial infarction; prior history of hypertension; prior history of heart failure; Type 2 diabetes; b-blocker treatment; creatinine; left ventricular ejection fraction; and NT-proBNP. All-cause mortality was used for the primary outcome measure (rather than cardiac mortality), as availability of data relating to cause of death was inconsistent among participants, part icularly for those recruited later in the study. The ethnicity of patients was based on grandparental information and was selfdeclared. Patients identified as being of Maori/ Pacific ancestry (one or more Maori or Pacific Island grandparent), of European descent (two or more European grandparents), Asian (one or more Asian grandparent) or were classified as other (two or more grandparents of other or unknown ethnicity). The power of this study to assess the relationship between haplotype and total mortality was estimated assuming 80% power and 2-tailed a = 0.05. Conservative estimates resulted in 80% power to detect a significant association with a hazard ratio of ≥2.00. All p-values <0.05 were reported. All analyses were performed using SPSS version 16.0 (SPSS Inc., IL, USA).
Results n Baseline cohort characteristics
The patient characteristics of the Coronary Disease Cohort Study are shown in Table 1 .
The average age at the time of recruitment was 66.7 years (range 18.7-100.0 years) and 70.4% of participants were male. For admission to the study all patients had a diagnosis of acute coronary syndromes; 51.8% had a diagnosis at discharge of non ST-elevation MI, 19.6% had ST-elevation MI and 28.6% were diagnosed with unstable angina. Throughout the 3-year follow-up period, cumulative mortality was 15.1% (n = 134).
n EDNRA polymorphisms Genotypes were obtained for >90% of the 1007 coronary disease cohort study (CDCS) patients. The genotype frequencies for each of the five SNPs are shown in Table 2 . Genotype frequencies were in accordance with HapMap data for the Northern and Western European ancestry population and where data was n EDNRA haplotypes PHASE software for haplotype estimation identified 20 different EDNRA haplotypes (combinations of individual SNPs) in the cohort (Table 3) . Of these 20 haplotypes, ten occurred at a frequency of greater than 1%. The 20 haplotypes identified by PHASE software resulted in 69 possible haplotype combinations, as each participant possesses two alleles and therefore two EDNRA haplotype copies. Of these 69 haplotype combinations, 18 occurred at a frequency of greater than 1%. Owing to the large number of haplotype combinations, and the low frequency at which many of these haplotypes occurred, participants were grouped according to their number of major haplotypes (defined by the major allele at each SNP locus) for all subsequent analyses. This resulted in three different haplotype groups, as patients could either carry 0, 1 or 2 copies of the major haplotype. When grouped according to the number of major alleles, 11% (n = 95) of participants had two major alleles, 
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future science group 53% (n = 476) had one major allele and 36% (n = 326) had 0 copies of the major haplotype. (Figure 2 ). This low-risk group had a total mortality of 7.4% compared to 13.1% for those carrying 1 copy and 20.2% for those with 0 copies of the major haplotype (log-rank p = 0.001). The association between EDNRA haplotype and mortality remained significant in Cox proportional hazards analysis that adjusted for the established predictors of increased risk: age of admission into the study; gender; ethnicity; prior history of MI; prior history of hypertension; prior history of heart failure; Type 2 diabetes; b-blocker treatment; left ventricular ejection fraction; plasma creatinine; and NT-proBNP (p < 0.0001; Table 5 ). Each copy of the EDNRA 'major' haplotype conferred a 2.16-fold reduced risk of mortality when compared to those individuals with 0 copies of the EDNRA major haplotype.
discussion
This study investigated haplotypes, defined by five polymorphisms within the EDNRA gene, for associations with clinical outcome in patients with established CAD. We have identified a 'low-risk' EDNRA haplotype that was associated with a better outcome in coronary disease patients. The pathological mechanisms by which EDNRA haplotype might influence survival in these patients are unknown at present, as haplotype was not associated with hypertension or prognostic factors such as left ventricular ejection fraction or NT-proBNP levels.
The endothelin system performs a number of important biological roles in addition to blood pressure regulation. ET-1 has inotropic actions, greatly increasing the contractility of both the vascular smooth muscle and cardiac muscle, and also enhances the contractile response of cardiomyocytes [6, 28] . Although an upregulated endothelin pathway may have short-term beneficial effects by providing inotropic support for the failing myocardium, prolonged stimulus by an upregulated endothelin system, perhaps via overactive ET-A receptors, might have maladaptive effects on myocardial structure and function [6] . ET-1 also has potent hypertrophic effects on cardiac myocytes, which suggests that it may play an important role in cardiac remodeling [6] . An upregulated endothelin system could therefore contribute to excessive hypertrophy of the myocardium, resulting in poorer outcomes in patients in the medium to long term [6] .
Previous studies of individual poly morphisms within the endothelin system have demonstrated associations with increased blood pressure, particularly in overweight people [29] , essential hypertension [8] and increased arterial stiffness [30] . While we found no association between EDNRA haplotype and hypertension or blood pressure in our study, this finding may have been confounded by pharmacotherapy. We did, however, observe a significant association between the EDNRA haplotype, BMI and Type 2 diabetes age of onset. There have been several studies demonstrating that endogenous endothelin may contribute to endothelial dysfunction in obesity and Type 2 diabetes, possibly via impaired availability of nitric oxide [31, 32] . In addition, increased endogenous endothelin action reportedly contributes to insulin resistance in skeletal muscle of obese humans [33] . Although links have been established between the endothelin system and Type 2 diabetes, the reported association with Type 2 diabetes age of onset in this current study was based on a small subset of CDCS participants. As a result further replication of the association between EDNRA and Type 2 diabetes is required. However, we propose that genetic variation within the EDNRA gene is associated with augmented endothelin receptor activity, and may promote endothelial dysfunction. Individuals with a high BMI and/or Type 2 diabetes may be particularly affected, and this may lead to an over-representation of these abnormalities among coronary patients without the major EDNRA haplotype. Diabetes is well-established as a major risk factor for CHD. The observed earlier age of onset of diabetes in patients without the major haplotype may contribute to poorer outcomes in these patients due to a longer burden of disease. The exact mechanisms by which this may occur are currently unknown. As the SNPs investigated do not alter the protein sequence of EDNRA and are not located in the regulatory regions of the gene, these hypotheses could be explored by further functional studies and through experimental physiological challenges to individuals with and without the major haplotype.
Limitations
CHD is a disease with multifactorial pathogenesis and many variants are involved in its develop ment. This study reported a candidate gene approach, investigating genetic variation in the EDNRA gene based on the established role of the endothelin system in CHD. However, in recent years genome-wide association studies have emerged as a useful tool in assessing genetic variation across the entire human genome on disease development. Although several genome-wide association studies have been performed to investigate the genetic basis of CHD, to date none of these studies have identified an association with the EDNRA locus. However, it is important to note that the majority of these studies have identified genomic regions associated with the risk of developing CHD with few studies investigating associations with cardiovascular outcomes in patients with established disease. Despite this, the findings of this current study will need to be validated in future cohorts of coronary disease patients. 
Conclusion
The findings from this research highlight the potential importance of the endothelin system, and in particular the EDNRA gene in CAD. This study provides further evidence that complex diseases such as CAD arise from the interaction of multiple genetic variants each conferring modest risk. The identification of EDNRA haplotypes that are associated with mortality in this coronary disease cohort, suggests that genetic variation within the endothelin system may contribute to disease propensity and progression. Subsequent investigation of EDNRA haplotypes in further cohorts, as well as functional studies of the influence of these variants on receptor activity will be required to further validate these findings.
Future perspective
The field of cardiovascular genetics is evolving rapidly. Candidate gene studies and current genome-wide association technology have yielded many genomic loci that occur commonly in the population and have modest effects on the risk of developing CHD. Although these studies have provided a wealth of information on the genetic basis of CHD, the regions identified to date account for only a small proportion of the heritability of this complex disease. The resulting missing heritability may be explained in the future by the identification of gene variants that although occur at low frequencies in the general population have much greater effects on coronary disease pathology in patient subgroups. Elucidating the genetic basis of this complex disease has the potential to provide new insights into not only the pathogenesis, but also the diagnosis and treatment of CHD. Genetic studies may also lead to the identification of new thera peutic targets, and in addition could help identify individuals with established CHD that are at greatest risk of having adverse outcomes.
executive summary

Background
The endothelins are a family of potent vasoconstrictors. The important biological functions of endothelin are mediated by the endothelin type-A and endothelin type-B receptors, encoded by the EDNRA and EDNRB genes. EDNRA genetic variation has been associated with essential hypertension and other cardiovascular phenotypes.
Methods
Coronary disease patients were genotyped for five polymorphisms within the EDNRA gene. EDNRA genotypes and haplotypes were investigated for associations with cardiovascular risk factors and mortality over a median 3.8 years follow-up.
Results
The major EDNRA haplotype was associated with an older age of Type 2 diabetes onset and a smaller BMI. The major EDNRA haplotype was associated with better survival after adjustment for established predictors of increased risk.
Discussion
We propose that genetic variation within the EDNRA gene is associated with augmented endothelin receptor activity and may promote endothelial dysfunction. Individuals with high BMI or Type 2 diabetes may be particularly affected. The earlier age of Type 2 diabetes onset in patients without the major haplotype may contribute to poorer outcomes in these patients due to a longer burden of disease. The mechanisms by which genetic variation within EDNRA affects clinical outcomes in coronary disease could be explored by further functional studies.
